๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Modeling multifactorial aspects of disease and drug therapy

โœ Scribed by W.D. Wosilait; M.P. Ryan; R.H. Luecke

Publisher
Elsevier Science
Year
1986
Weight
706 KB
Volume
7
Category
Article
ISSN
0270-0255

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Estimation of disease risk under bivaria
Estimation of disease risk under bivariate models of multifactorial inheritance
โœ Dr. Steven O. Moldin; John P. Rice; Paul Van Eerdewegh; Irving I. Gottesman; L. ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 898 KB

Adjunct consideration of both qualitative (affection status) and quantitative (correlated liability indicator) information to define a bivariate phenotype can increase considerably the accuracy and efficiency of disease risk estimation. A general approach for calculating morbid risks to offspring on

Alternative drug delivery approaches for
Alternative drug delivery approaches for the therapy of inflammatory bowel disease
โœ Yvette Meissner; Alf Lamprecht ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 457 KB ๐Ÿ‘ 1 views

This article shall give an overview on drug delivery systems for new therapeutic strategies in the treatment of inflammatory bowel disease. The various features of the different approaches allowing locally restricted drug delivery to the inflamed colon are discussed including the main physiological

Delay to institution of therapy and indu
Delay to institution of therapy and induction of remission using single-drug or combinationโ€“disease-modifying antirheumatic drug therapy in early rheumatoid arthritis
โœ Timo Mรถttรถnen; Pekka Hannonen; Markku Korpela; Martti Nissilรค; Hannu Kautiainen; ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 59 KB ๐Ÿ‘ 2 views

## Abstract ## Objective To study the impacts of 1) the delay from the onset of symptoms to the institution of diseaseโ€modifying antirheumatic drug (DMARD) therapy, 2) two treatment strategies (treatment with a combination of DMARDs or with a single drug), and 3) the presence of HLAโ€“DRB1 alleles (